Cardiac Amyloidosis Treatment Medication to stabilize the TTR protein (for ATTR, not AL) Medication to “silence” the TTR gene and prevent the body from producing the TTR protein (for ATTR, not AL) Medications to reduce swelling or control irregular heartbeat. A pacemaker to regulate the heartbeat.

Pfizer’s tafamidis arrived in the U.S. in 2019 with a vastly discounted list price over rival transthyretin amyloidosis drugs. But its $225,000-a-year tag still seems too much for many heart patients.

The Health Canada indication for tafamidis is for the treatment of adult patients with cardiomyopathy due to TTR-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization. Tafamidis is available as a 20 mg capsule.

The reports suggesting digoxin is contraindicated due to increased toxicity are of poor quality [5–7], and lack control comparator since cardiac sudden death is common in cardiac AL amyloidosis.

61 Mg Vyndamax Tafamidis Capsule, Rs 120000 /box Arysta Lifescience India Limited | ID: 23171454288.

The most common side effects with Vyndaqel (seen in more than 1 patient in 10) are urinary tract infection (infection of the structures that carry urine), vaginal infection, upper abdominal pain (stomach ache) and diarrhoea.

Prognosis in ATTR amyloidosis is generally better than in AL amyloidosis, though both forms of the disease still carry a high annual mortality. Various staging systems have been proposed for AL amyloidosis, with the majority focusing primarily on the degree of cardiac involvement.

Recommended Dosage The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily. VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis [see CLINICAL PHARMACOLOGY].

Since TTR levels are lower with moderate hepatic impairment, exposure of tafamidis relative to the amount of TTR is sufficient to maintain stabilization of the TTR tetramer in these patients.

Tafamidis is a transthyretin (TTR) stabilizer that selectively binds to TTR at the thyroxine binding sites and stabilizes the tetramer of the TTR transport protein, slowing dissociation into monomers which is the rate-limiting step in the amyloidogenic process.

Canadian labeling: Additional contraindications not in the US labeling: Hypersensitivity to tafamidis or any component of the formulation. Note: Tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel) are not substitutable on a per mg basis. Tafamidis (Vyndamax): 61 mg once daily. Tafamidis meglumine (Vyndaqel): 80 mg once daily.